INTRODUCTION
Cardiovascular disease remains the leading cause of morbidity and death in the Western world and is rapidly becoming the number one killer in the developing countries. 1 Atherothrombosis, characterized as atherosclerotic plaque disruption with superimposed thrombosis, is the most important cause of acute coronary syndromes and cardiovascular death. [2] [3] [4] The underlying pathology of most acute coronary syndromes involves coronary atherosclerosis with ruptured plaques, followed by acute occlusive or subocclusive thrombus formation. [2] [3] [4] The term vulnerable plaque has been introduced to identify thrombosis-prone plaques and plaques with a high probability of undergoing rapid progression, thus becoming culprit plaques. Recently, the term vulnerable patient has been suggested in recognition of contributing culprit factors including vulnerable blood (prone to thrombosis) and vulnerable myocardium (prone to fatal arrhythmia) that identify patients with a high likelihood of having cardiac events develop in the near future. 5 Investigators have shown multiple rupture-prone or ruptured plaques in a wide range of cardiovascular patient populations. [6] [7] [8] [9] [10] [11] As a result, the concept of pan-coronary vulnerability has been introduced to emphasize the importance of going beyond a single vulnerable plaque and evaluating the total arterial tree as a whole. [12] [13] [14] Noninvasive visualization of evolving arterial thrombus would facilitate detection of thrombosis burden in patients with acute coronary syndrome. Similarly, noninvasive imaging techniques may enhance our current understanding of the natural history and of the pathophysiologic mechanisms of atherothrombosis. Arterial thrombi are not reliably detected by current diagnostic techniques. Intravascular ultrasound and angiography are invasive and use indirect and nonsensitive criteria for thrombus detection. Angioscopy is highly invasive and not widely available. 15 Among the different imaging modalities, cardiovascular magnetic resonance (CMR) is emerging as the most comprehensive noninvasive in vivo imaging modality for atherothrombosis. [16] [17] [18] In this review we will address the current and evolving developments in CMR with a focus on coronary plaque imaging and in vivo molecular imaging of coronary thrombosis. With further development, CMR imaging of atherothrombosis in the diseased vessel walls (carotid arteries, thoracic and abdominal aorta, and coronary arteries) may prove to be clinically beneficial in identifying vulnerable patients.
DIAGNOSIS OF VULNERABLE PLAQUES
On the basis of autopsy studies, a number of major and minor criteria for defining vulnerable plaques have been proposed. 5 These criteria of vulnerability (Tables 1 and 2 ) include morphologic features (eg, size of lipid core and thickness of fibrous cap), as well as markers of plaque activity (eg, plaque inflammation, superficial platelet aggregation, and fibrin deposition). Most of the proposed features of plaque vulnerability are based on cross-sectional and retrospective studies of culprit lesions. Noninvasive surrogate markers, such as coronary vessel wall thickness and plaque burden, together with markers of plaque activity, may supplement or improve cardiovascular risk stratification especially in patients with an intermediate cardiovascular risk. Noninvasive imaging techniques provide a mechanism for prospective outcome studies to determine whether identifying asymptomatic vulnerable patients may allow for therapeutic interventions to reduce clinical cardiovascular events.
with suspected coronary disease in a prospective multicenter study. 19 Overall, coronary MRI had an accuracy of 72% (95% confidence interval, 63%-81%) in diagnosing coronary artery disease (CAD) (defined as Ն50% diameter reduction on x-ray angiography). 19 Coronary MRI was particularly helpful for excluding left main coronary artery or 3-vessel disease, with a negative predictive value of 100%. 19 However, coronary MRI remains technically demanding, as respiratory and cardiac motion limits the useful data acquisition window. Imaging the walls of coronary vessels is particularly challenging because of their wall thickness (0.5-2 mm), tortuous 3-dimensional (3D) course of the coronary vessels, and close proximity to epicardial fat, coronary blood, and myocardium. Motion compensation strategies for coronary vessel wall imaging are therefore even more stringent than for "lumen" coronary MRI. Technical solutions to meet the challenges of coronary vessel wall imaging have been developed, allowing more consistent visualization of the proximal and mid portions of the native coronary vessel walls.
CARDIAC MOTION
Because of the rapid intrinsic cardiac motion during the cardiac cycle, synchronization of data acquisition to the electrocardiogram is mandatory. A short cardiac acquisition window of less than 10% of the cardiac cycle in either end systole or mid diastole (periods of relative myocardial diastasis) with a well-defined delay to the R wave is typically used for data acquisition. 20, 21 These measures are essential to avoid cardiac motion-induced artifacts but reduce the scan efficiency by a large scale.
Subject-specific mid-diastolic acquisition usually provides the most optimal imaging in subjects with a heart rate lower than 80 beats/min. For subjects with heart rates greater than 80 beats/min, minimal motion is usually during end systole. The timing of the subjectspecific image acquisition can be assessed from a cine data set in the 4-chamber view by visual inspection or automated analysis. The length of the mid-diastolic or end-systolic rest period (which typically varies from 50-350 milliseconds) is heart rate-dependent. 21 Subjects with heart rates greater than 60 beats/min may benefit from ␤-blockers to slow their heart rates and to increase their rest period duration. A drawback of imaging within a 50-to 100-millisecond time window per cardiac cycle is that the total imaging time is relatively long. To overcome this drawback, one may use a longer cardiac acquisition window with intra-R-R interval motion correction. 22 Combining the motion-corrected segments produced a high-resolution image ( Figure 1 ).
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RESPIRATORY MOTION COMPENSATION
Normal diaphragmatic excursion (10-20 mm) may exceed a multiple of the coronary vessel wall thickness (0.5-2 mm). 23 Thus respiratory motion compensation is critical for coronary vessel wall imaging.
Initial approaches for visualizing cross sections of the proximal coronary vessel wall used 2-dimensional (2D) breath-hold techniques with mid-diastolic image acquisition. 24 This approach has variable image quality because many patients cannot hold their breath for the required 15-to 20-second time period. Furthermore, the limited spatial coverage of 2D techniques limits the clinical potential because evaluation of the entire proximal coronary vessel wall is likely to be important.
To compensate for respiratory motion during a free-breathing examination, a 2D-selective pencil beam navigator placed on the right hemidiaphragm can be used to monitor respiration and to perform real-time gating and slice tracking. 19 The use of navigator echoes that record and correct for diaphragmatic motion 25 allows for free-breathing and removes the time constraints of the breath-hold approach, thereby allowing for submillimeter spatial resolution. 26, 27 Similar to coronary MRI, coronary vessel wall imaging can be combined with the navigator technique and can be extended to 3D acquisitions providing a higher signal-to-noise ratio and improved vessel coverage. 28 The major drawbacks of freebreathing coronary MRI with respiratory navigator gating are low navigator efficiency and prolonged scan time as a result of irregular breathing patterns. A novel technique has been presented, which enables the calibration of a 3D affine respiratory motion model to the individual motion pattern of the patient. 29 Preliminary Modified from Naghavi et al. 5 results have shown that this approach increases the scan efficiency without sacrificing image quality and has the potential to be more robust for routine clinical usage.
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CORONARY PLAQUE BURDEN
Early in vivo coronary vessel wall imaging studies used a 2D fat-suppressed fast spin echo technique. 24, 30 Coronary blood signal was suppressed by use of a double inversion pulse, 31 leading to optimal contrast between lumen and vessel wall. This "black-blood" approach has been implemented in both a 2D breath-hold mode 24 and a free-breathing mode 30 and allows for visualization of cross-sectional images of the left anterior descending artery and right coronary artery vessel wall both in healthy subjects and in patients with CAD. In-plane spatial resolution of these first implementations varied from 0.46 ϫ 0.46 mm to 0.5 ϫ 1 mm, with a typical slice thickness of 3 to 5 mm. Wall thickness was found to be higher in patients with CAD when compared with normal healthy subjects. 24, 30 Because of the highly tortuous path of the coronary artery system, cross-sectional vessel wall imaging of the coronary arteries is time-inefficient, therefore making a vessel-targeted approach more desirable. Such an approach was implemented via a 3-point plan scan method 32 and combined with a modified black-blood prepulse (local inversion), 28 which allows acquisition of 3D stacks along the major axis of the coronary artery system. This novel technique allowed for visualization of the proximal and mid portions of the right coronary artery and left anterior descending artery wall with good contrast between coronary blood and the vessel wall. 28 Free-breathing 3D black-blood coronary CMR identified an increased coronary vessel wall thickness with preservation of lumen size in patients with nonsignificant CAD, consistent with a "Glagov-type" outward arterial remodeling (Figure 2) . 33 Acquisition of isotropic voxels, 34 which facilitates reconstruction of arbitrary views, may prove useful for reconstruction of cross-sectional vessel wall images along a user-defined path from a single 3D data set.
CORONARY ATHEROTHROMBOSIS IMAGING BY CMR
CMR has shown great promise as a comprehensive imaging modality for in vivo imaging of atherothrombo- sis. Multispectral MRI relies on the fact that the magnetic resonance (MR) signal emitted by water protons ( 1 H) varies according to their molecular environment. In principle, each plaque component has an MR-specific "ZIP code," which is composed of the T 1 and T 2 relaxation times, proton density, molecular diffusion, magnetization transfer, and so on. 35 Because there is an overlap of signal intensities between the different sequences and the different plaque components, unique identification of plaque components can be difficult. Nevertheless, multispectral MRI has been successfully demonstrated for plaque characterization in ex vivo vessel specimens, [35] [36] [37] in experimental animals, 17, 38, 39 and in human carotid artery 18, 40 and aorta 41, 42 in vivo. Currently, spatial resolution remains the limiting factor for detailed coronary plaque characterization. On the basis of simulations and phantom studies, it was demonstrated that at least 1 pixel is needed across the different tissue layers of the vessel wall (fibrous cap, lipid pool, smooth muscle) to characterize different vessel wall components reliably. 43 Furthermore, respiratory motion correction needs to be as accurate as 3 times the thickness of the tissue layer. 43 In principle, these boundaries could be met with the current navigator-based 3D coronary vessel wall sequences. 28, 33 However, from a practical perspective, high-resolution imaging causes a reduction in the signal-to-noise ratio. Therefore the use of exogenous targeted contrast agents, 44 ,45 intravascular coils, 46 and higher magnetic field strengths 47 may be required for detailed vessel wall imaging. Different MR probes have been developed to study various biologic processes (eg, thrombosis, angiogenesis, inflammation, and neoplasia) and diseases (eg, cancer, cardiovascular disease, stroke, and diabetes) by targeting a spectrum of molecular markers such as fibrin, selectins, and integrins. Most of these agents are in the preclinical stage.
Recently, advances have been made with in vivo imaging of arterial thrombus by fibrin-binding molecular MR contrast agents. 44, 45 Direct imaging of arterial thrombus by targeted or "molecular" contrast agents (which are engineered to bind to specific target molecules) is advantageous to classical noncontrast multispectral MRI because the demand for high spatial resolution and motion compensation strategies is less stringent. Furthermore, even though several studies have shown high sensitivity of MRI in the detection of carotid and aortic thrombi, [48] [49] [50] differentiation between complex atherosclerotic plaques and mural thrombosis remains difficult because of the complex composition (eg, platelets, fibrin, and red blood cells) of thrombus and resultant complex MR signal characteristics on T 1 -, T 2 -, and proton density-weighted images of arterial thrombi. The concept of targeted imaging was first introduced over a decade ago and has since been further developed by Weissleder and colleagues [51] [52] [53] for MRI and optical imaging in recent years. The advantage of CMR molecular plaque imaging is the potential for relatively high spatial resolution. The limitation is the inherently low sensitivity of MR contrast enhancement technology, requiring a relatively high target molecule concentration (Ͼ50-100 mol/L gadolinium at target site) for sufficient signal amplification. Initial attempts were made with targeting fibrin, [54] [55] [56] which is abundant in arterial clots and plays an important role in acute coronary syndromes and stroke. In vivo MRI of acute and subacute thrombosis after plaque rupture in an animal model of aortic atherosclerosis has been implemented by use of a small-molecule fibrin-binding peptide derivative, EP-1873 (EPIX Pharmaceuticals Inc, Cambridge, Mass) ( Figure 3) . 44 This novel molecular agent allowed for imaging of large lumen encroaching thrombi as well as submillimeter mural thrombi with signal enhancement of the entire thrombus and excellent differentiation from the vessel wall. Combining the advent of fibrin-binding molecular MR contrast agents and advances in coronary MRI techniques offers the potential for direct imaging of coronary thrombosis. The feasibility of this approach was demonstrated by use of a gadolinium-based fibrinbinding contrast agent, EP-2104R (EPIX Pharmaceuticals Inc), in a swine model of native coronary thrombus ( Figure 4 ) and in-stent thrombosis by use of MR-lucent stents ( Figure 5) . 45 Potential applications for direct thrombus imaging include detection and evaluation of acute coronary syndromes and ischemic strokes.
Integrins, such as ␣ v ␤ 3 , are associated with angiogenesis, which is a critical feature of plaque development in atherosclerosis, and likely play a key role in plaque rupture leading to myocardial infarction or stroke. Increased angiogenesis is detected as signal enhancement in the MR signal averaged throughout the abdominal aortic wall among hyperlipidemic rabbits that receive ␣ v ␤ 3 -targeted, paramagnetic nanoparticles. 57 Histology and immunohistochemistry confirm marked proliferation of angiogenic vessels within the aortic adventitia among cholesterol-fed, atherosclerotic rabbits in comparison with a sparse incidence of neovasculature in control animals.
Vascular inflammation and associated endothelial activation are believed to play an integral role in the initiation and progression of atherosclerosis. Endothelial cells express adhesion molecules such as E-and Pselectin, which facilitate adhesion and migration of monocytes. Differentiation of monocytes into macrophages and subsequent digestion of lipoproteins by macrophages occur in a later stage and eventually lead to the accumulation of lipid-filled macrophages, which are believed to be a precursor of rupture-prone vulnerable plaque. Early endothelial activation has been detected by use of a novel MR contrast agent in rats with brain inflammation (after interleukin-1␤-and tumor necrosis factor ␣-induced E-and P-selectin upregulation) 58 and in focal ischemia in mice brains. 59 This novel gadoliniumlabeled contrast agent, gadolinium-diethylenetriamine pentaacetic acid-B(sLe x )A, 60 consists of the Sialyl Lewis x (sLe x ) carbohydrate, which interacts with both E-and P-selectin. These promising results encourage further studies including assessment of E-and P-selectin upregulation in early atherosclerotic lesions in the coronary arteries.
SUMMARY
Atherothrombosis, defined as atherosclerotic lesion disruption with superimposed thrombus formation, is the major cause of acute coronary syndromes and cardiovascular death. CMR imaging of coronary atherothrombosis is challenging because of the small caliber of the vessels combined with respiratory and cardiac motion. Freebreathing 3D CMR coronary vessel wall imaging has 45 ) enabled in vivo quantification of coronary plaque burden and remodeling as a marker of subclinical CAD. Molecular imaging via novel target-specific contrast agents such as fibrin-binding agents to detect arterial thrombus shows great promise as the new frontier in noninvasive imaging. Advances in molecular imaging and CMR techniques offer the potential for direct imaging of coronary thrombosis and in-stent thrombosis by use of novel fibrin-binding molecular MR contrast agents. Although the current role of noninvasive CMR imaging of atherothrombosis remains investigational, these techniques should enhance our understanding of the natural history of acute coronary syndromes and thereby facilitate strategies to prevent acute coronary syndromes and cardiovascular death in vulnerable patients.
